BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
May 04 2021 - 7:00AM
BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced that
Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel,
will participate in two upcoming virtual healthcare investor
conferences.
Presentation Details:
Event: BofA Securities 2021 Virtual Health Care
Conference
Format: Fireside Chat
Date: Tuesday, May 11, 2021
Time: 8:45 AM ET
Event: UBS Global Healthcare Virtual
Conference
Format: Corporate Presentation
Date: Tuesday, May 25, 2021
Time: 2:00 PM ET
Live webcasts from the BofA and UBS presentations and
accompanying presentation materials will be accessible through the
Investors section of the Company's website at
www.bioxceltherapeutics.com. Following the conferences, the
webcasts will be archived on the BioXcel Therapeutics, Inc. website
for at least 30 days.
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical
company utilizing artificial intelligence approaches to develop
transformative medicines in neuroscience and immuno-oncology.
BioXcel's drug re-innovation approach leverages existing approved
drugs and/or clinically validated product candidates together with
big data and proprietary machine learning algorithms to identify
new therapeutic indices. BioXcel's two most advanced clinical
development programs are BXCL501, an investigational, proprietary,
orally dissolving thin film formulation of dexmedetomidine for the
treatment of agitation and opioid withdrawal symptoms, and BXCL701,
an investigational, orally administered, systemic innate immunity
activator in development for the treatment of aggressive forms of
prostate cancer and advanced solid tumors that are refractory or
treatment naïve to checkpoint inhibitors. For more information,
please visit www.bioxceltherapeutics.com.
BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com
Investor Relations:
Mary Coleman
BioXcel Therapeutics, VP of Investment Relations
MColeman@bioxceltherapeutics.com
1.475.238.6837
John Graziano
Solebury Trout
jgraziano@soleburytrout.com
1.646.378.2942
Media:
Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com
1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024